6533b828fe1ef96bd1288330
RESEARCH PRODUCT
The Barrett‐associated variants at GDF 7 and TBX 5 also increase esophageal adenocarcinoma risk
Christian EllJan‐hinnerk HoferHorst NeuhausAndrea MayTania NoderKatharina WeiseJakob R. IzbickiChristian GergesMarkus M. NöthenHauke LangClaudia SchmidtJessica BeckerThomas RöschMarino VeneritoLothar VeitsYogesh K. VashistSophie K. M. HeinrichsMichael KnappAnne C. BöhmerMichael ViethAndreas HackelsbergerMichael ArrasElfriede BollschweilerConstantin J. AhlbrandRupert MayershoferHendrik MannerTimo HessJohannes SchumacherNils KosiolNicole KreuserJosef WeismüllerDietmar LorenzSebastian J. HoferPeter MalfertheinerInes GockelOrestis LyrosKatja OttThomas SchmidtArnulf H. HölscherRalf KiesslichBrigitte SchumacherOliver PechMario AndersMarkus Moehlersubject
0301 basic medicineCancer ResearchCase-control studyGenome-wide association studyLocus (genetics)Biologymedicine.diseaseBioinformaticshumanitiesALDH1A203 medical and health sciences030104 developmental biologymedicine.anatomical_structureOncologyGenetic variationCancer researchmedicineAdenocarcinomaRadiology Nuclear Medicine and imagingEsophagusGenedescription
Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) represent two stages within the esophagitis-metaplasia-dysplasia-adenocarcinoma sequence. Previously genetic risk factors have been identified that confer risk to BE and EAC development. However, to which extent the genetic variants confer risk to different stages of the BE/EAC sequence remains mainly unknown. In this study we analyzed three most recently identified BE variants at the genes GDF7 (rs3072), TBX5 (rs2701108), and ALDH1A2 (rs3784262) separately in BE and EAC samples in order to determine their risk effects during BE/EAC sequence. Our data show that rs3072 at GDF7 and rs2701108 at TBX5 are also associated with EAC and conclude that both loci confer disease risk also at later stages of the BE/EAC sequence. In contrast, rs3784262 at ALDH1A2 was highly significantly associated with BE, but showed no association with EAC. Our data do not provide evidence that the ALDH1A2 locus confers equal risk in early and late stages of BE/EAC sequence.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-01-18 | Cancer Medicine |